Skip to main content

Table 3 Molecular and clinical characteristics of the analyzed sample cohort

From: DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

Clinicopathological factors Number of samples
Median age at diagnosis 65 (range 32-85)
Histological grade  
Grade 1 18 (24%)
Grade 2 38 (50.7%)
Grade 3 19 (25.3%)
Response  
Progressive Disease 7 (9.5%)
PR, MC or SD 67 (90.5%)
Tumor size  
T2 3 (4%)
T3 47 (62.7%)
T4 25 (33.3%)
Lymph node metastasis  
N0 25 (33.3%)
N1 29 (38.7%)
N2 21 (28%)
Distant metastasis  
M0 66 (88.0%)
M1 9 (12%)
Stage  
Stage 2 18 (24%)
Stage 3 46 (61%)
Stage 4 11 (15%)
TP53 mutations  
Wild type 55 (73.3%)
Mutant 20 (26.7%)
Estrogen receptor status  
Positive 65 (86.7%)
Negative 10 (13.3%)
Progesteron receptor status  
Positive 58 (77.3%)
Negative 17 (22.7%)
ErbB2 receptor status  
Positive 11 (25%)
Negative 33 (75%)
Survival  
> 5 years 20 (26.7%)
< 5 years 55 (73.3%)
  1. PR: partial response; MC: minimal change; SD: stable disease. Lymph node status was assessed clinically prior to neoadjuvant therapy and does not necessarily correspond to pathological lymph node status. In this context N0 means that no enlarged nodes were felt prior to therapy. N1 corresponds to the presence of palpable and movable ipsilateral axillary lymph nodes suspicious of the presence of metastases while N2 corresponds to fixed ipsilateral axillary lymph nodes and thus very likely to the presence of tumours.